

RECEIVED

APR 29 2002




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,962	11/08/2000	Bernhard Hauer	49041	7018

7590 03/27/2002
Keil & Weinkauff
1101 Connecticut Avenue NW
Washington, DC 20036



EXAMINER

BHATTI, TAHIRA H

ART UNIT PAPER NUMBER

1627

DATE MAILED: 03/27/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/674,962			



EXAMINER	
Tahira Bhatti	
ART UNIT	PAPER NUMBER
1627	5

DATE MAILED:

TECH CENTER 1600/2900

RECEIVED

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Tahira Bhatti whose telephone number is (703) 605-1203. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

Tahira Bhatti
Patent Examiner
Technology center 1600
Art Unit 1627
Nov 27, 2001

J. Venkat
DR. JYOTHSNA VENKAT PH.D.
SUPERVISOR, PATENT EXAMINER
TECHNOLOGY CENTER 1600

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirement for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(d).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial or ^{9B}substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or ^{9B}substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.



1

SEQUENCE LISTING

<110> Hauer, Bernhard
Schmid, Rolf D.
Enzelberger, Markus
Minning, Stephan

<120> Novel Peptide Fragments for Purifying Proteins

<130> 49041/Up

<140> 09/674,962

<141> 2000-11-08

<150> PCT/EP99/03469

<151> 1999-05-20

<160> 10

<170> WordPerfect version 6.1

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<222> 1..10

<223> sequence for purifying proteins

<221> unsure

<222> 2

<223> Xaa is an amino acid selected from the group consisting of Ala, Val, Phe, Ser, Met, Trp, Tyr, Asn, Asp and Lys, particularly preferably Phe, Ser, Asn, Asp and Lys, very particularly preferably Asn.

<221> unsure

<222> 4

<223> Xaa is an amino acid selected from the group consisting of Val, Ile, Phe, Pro, Trp, Tyr, Gln, Glu and Arg, particularly preferably Val, Ile, Phe, Pro, Gln, Glu and Arg,

<223> very particularly preferably Gln, Glu and Arg.

<221> unsure

<222> 5

<223> Xaa is an amino acid selected from the group consisting of Gly, Ile, Thr, Met, Trp, Tyr, Asn, Gln, Asp, Glu, Lys, Arg and His, particularly preferably Gly, Ile, Thr, Met, Trp, Tyr, Asn Asp, Glu, Arg and His,

<223> very particularly preferably Gly, Thr and Tyr.

<221> unsure

<222> 6

<223> Xaa is an amino acid selected from the group consisting of

TECH CENTER 1600/2900

APR 29 2002

RECEIVED

Sub
C1

B1

Val, Phe, Pro, Cys, Met, Trp, Asn, Glu, Arg and His, particularly preferably Val, Phe, Cys, Met, Trp, Asn, Arg and His, very particularly preferably Asn and Arg.

<221> unsure

<222> 8

<223> Xaa is an amino acid selected from the group consisting of Gly, Ser, Cys, Met, Trp, Asn, Glu, Lys and Arg, particularly preferably Gly, Ser, Cys, Met, Asn, Glu, Lys and Arg, very particularly preferably Gly and Lys.

<221> unsure

<222> 9

<223> Xaa is an amino acid selected from the group consisting of Gly, Ser, Cys, Met, Trp, Asn, Glu, Lys and Arg, particularly preferably Gly, Ser, Cys, Met, Asn, Glu, Lys and Arg, very particularly preferably Gly and Lys.

<400> 1

His Xaa His Xaa Xaa Xaa Cys Xaa Xaa Cys
1 5 10

<210> 2

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence for purifying proteins

<400> 2

His Gln His Glu Gly Arg Cys Lys Glu Cys
1 5 10

<210> 3

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence for purifying proteins

<400> 3

His Asn His Arg Tyr Gly Cys Gly Cys Cys
1 5 10

<210> 4

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Sequence for purifying proteins

<400> 4

His Arg His Gly Thr Asn Cys Leu Lys Cys
1 5 10

<210> 5
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Sequence for purifying proteins

<400> 5

His Ile His Gln Ser Asn Cys Gln Val Cys
1 5 10

<210> 6
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<221> unsure
<222> 1..59
<223> primer
<223> n is a, g, c, t or u

<400> 6

gcaataccat ggggcatnnn catnnnnnnn nntgtnnnnn ntgtgtgagg aagggcgag 59

<210> 7
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 7

cagttggaat tctagag 17

<210> 8
<211> 47
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 8

gcaataccat ggggcatcat catcatcatc atgtgaggaa gggcgag 47

<210> 9

4

<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 9

cagttggaat tctagag

17

<210> 10
<211> 44
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 10

gcaataccat ggggcatatt cataatcttg attgtcctga ttgt

44

Sub
Genes
B1
mal